PerCP/Cyanine5.5 anti-human GARP LRRC32 Antibody anti-GARP - 7B11,BioLegend,352514

Host

Mouse

Reactivity

Human

Application

FC -Quality tested

Platform ID

BAB383961341

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NamePerCP/Cyanine5.5 anti-human GARP LRRC32 Antibody anti-GARP - 7B11
Cat. No.352514
HostMouse
RRIDAB_2734371 (BioLegend Cat. No. 352513)AB_2734372 (BioLegend Cat. No. 352514)
IsotypeMouse IgG2b, κ
ReactivityHuman
ApplicationFC -Quality tested
ClonalityMonoclonal
Clone Number7B11
ConcentrationLot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in ourCertificate of Analysisonline tool.)
TargetGARP
ImmunogenLRRC32-DNA vaccination
PurityThe antibody was purified by affinity chromatography and conjugated with PerCP/Cyanine5.5 under optimal conditions.
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
StorageThe antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light.Do not freeze.
Regulatory StatusResearch Use Only

Scientific Background

Glycoprotein A Repetitions Predominant (GARP), also known as leucine rich repeat containing 32 (LRC32), is a 80 kD type I membrane glycoprotein with 20 leucine rich repeats in the extracellular portion of the protein. GARP was found on the surface of megakaryocytes, platelets, and activated Tregs (CD4+, CD25+, FoxP3+ cells) and serves as a receptor for latent TGF-β. Recent evidence suggests that GARP may play a role in controlling suppressor function of Tregs. A mutation in GARP has been reported in a large Samaritan kindred with Usher syndrome type 1, an autosomal recessive disease characterized by profound congenital sensorineural deafness, vestibular dysfunction, and progressive visual loss. In addition, it has been found that GARP mRNA is highly amplified in different tumors, which indicates that tumor cells may use GARP to express TGF-β or to capture TGF-β from their surroundings, resulting in local suppression of anti-tumor immune responses or the induction of Tregs.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.